Medipattern Announces Amended Financing Terms

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), is pleased to
announce today that in connection with its brokered private placement (the
"Offering") of common shares which was previously announced on May 28, 2012,
Medipattern and Industrial Alliance Securities Inc. (the "Agent") have agreed to
amend the terms of the Offering so that Medipattern shall now offer between
8,000,000 and 16,000,000 units ("Units") at a price of $0.25 per Unit, for
aggregate gross proceeds of a minimum of $2,000,000 and up to $4,000,000. 


Each Unit will consist of one common share and one-half of one common share
purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant will
entitle the holder thereof to purchase one common share at an exercise price of
$0.30 per common share at any time on or before the date that is 60 months
following the closing of the Offering, provided that if, at any time after the
date which is four months and one day following the closing date of the
Offering, the volume weighted average closing price of the common shares of
Medipattern on the principal market on which such shares trade is equal to or
exceeds $0.60 for 20 consecutive trading days, Medipattern may accelerate the
expiry date of the Warrants, in which event the Warrants will expire upon the
date (the "Accelerated Expiry Date") which is 20 days following the
dissemination of a press release by Medipattern announcing the Accelerated
Expiry Date.


All securities issued pursuant to the Offering will be subject to a four month
and one day hold period from the closing of the Offering as required by
applicable securities legislation and the rules of the TSX Venture Exchange.


The Offering is expected to close on or about July 4, 2012 or on such other date
as agreed to by Medipattern and the Agent. All other terms and conditions of the
Offering are the same as were announced on May 28, 2012. 


Medipattern plans to use the proceeds from the proposed private placement
financing to provide working capital for its current business, including its
focus on commercializing Visualize:Vascular(TM), and upon closing of the
transaction with MYTRAK(R) Health System Inc. announced on May 28, 2012, to
expand the business unit of MyTrak Mobile Health Solutions.


The securities offered in the placement have not been and will not be registered
under the United States Securities Act of 1933, as amended, (the "U.S.
Securities Act"), and may not be offered or sold within the United States or to,
or for the account or benefit of U.S. persons except in certain transactions
exempt from the registration requirements of the U.S. Securities Act.


About The Medipattern Corporation: 

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


Medipattern(R) is a registered mark of The Medipattern Corporation. Cadenza(TM)
and Visualize:Vascular(TM) are trademarks of the Medipattern Corporation. 


Forward-looking statements 

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.